Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Experiencing guilt after cancer treatment may sound unexpected, but it’s actually quite common. Clinical psychologist Catherine Powers, Ph.D., and senior social work counselor Kendolyn Shankle…
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
An abstract is unavailable.
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Agencje rejestrujÄ…ce leki, takie jak FDA czy EMA, mogÄ… dopuszczać leki w procedurze przyspieszonej lub warunkowo. Bywa, że jeÅ›li lek okaże siÄ™ nieskuteczny, może zostać…
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Childhood cancer survivors are at high risk of long-term iatrogenic events, in particular those treated with radiotherapy. The prediction of risk of such events is…
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this